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to	 troubleshoot	 and	 solve	 any	 problems	 I	 encountered	 during	my	 time	 in	 the	





















is	 a	 feature	 of	 conditions	 such	 as	 glaucoma.	 In	 addition	 to	 well-described	
mechanisms	 of	 retinal	 neuron	 injury	 in	 glaucoma,	 such	 as	 mitochondrial	
dysfunction	and	oxidative	stress,	energetic	failure	has	also	been	postulated.	In	this	
thesis,	emphasis	is	directed	towards	investigating	the	retinal	effects	of	creatine,	




D-aspartate	 (NMDA)-induced	 retinal	 excitotoxicity.	 As	 there	 exists	 no	 gold	
standard	marker	for	RGC	for	the	purposes	of	neuroprotection	studies,	we	aimed	
to	 compare	 four	 recent	 ganglion	 cell	 markers	 by	 retinal	 whole-mount	
immunohistochemistry	and	observe	how	they	changed	over	time	following	NMDA	
exposure.	We	found	that	NMDA-induced	RGC	injury	was	maximal	within	the	first	





The	 second	paper	addresses	 the	effects	of	 creatine	 in	models	of	 retinal	






oral	 creatine	 supplementation	 in	 rat	 models	 of	 NMDA-induced	 retinal	
excitotoxicity	and	retinal	ischaemia	were	examined.	RGC	reductions	were	found	
to	 be	 up	 to	 70%	 but	 these	 losses	 were	 not	 significantly	 reduced	 by	 creatine	
supplementation.	 When	 apoptotic	 levels	 were	 assessed,	 there	 remained	 no	
significant	 difference	 between	 the	 creatine-fed	 and	 control	 group	 of	 rats	 that	
















































ADP	 	 	 Adenosine	triphosphate	
ALS	 	 	 Amyotrophic	lateral	sclerosis	
ATP	 	 	 Adenosine	triphosphate	
CNS	 	 	 Central	nervous	system	
CK	 	 	 Creatine	kinase	
CRT-1	 	 	 Creatine	transporter	
DNA	 	 	 Deoxyribonucleic	acid	
FBS	 	 	 Fetal	bovine	serum	
GABA	 	 	 γ-aminobutyric	acid		
GCL	 	 	 Ganglion	cell	layer	
INL	 	 	 Inner	nuclear	layer	
IOP	 	 	 Intraocular	pressure	
MPTP	 	 	 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	
NMDA		 	 N-methyl-D-aspartate	
NBF	 	 	 Neutral-buffered	formalin	
NTG	 	 	 Normal	tension	glaucoma	
OCT	 	 	 Optical	coherence	tomography	
ONL	 	 	 Outer	nuclear	layer	
PBS	 	 	 Phosphate	buffered	saline	
POAG	 	 	 Primary	open-angle	glaucoma	
RBPMS		 	 RNA-binding	protein	with	multiple	splicing	
RGC	 	 	 Retinal	ganglion	cell	
SAMe	 	 	 S-adenosyl-L-methionine	
SEM	 	 	 Standard	mean	of	error	
Tdt	 	 	 Terminal	deoxynucleotidyl	transferase	






Degeneration	of	 neuronal	 cells	 (i.e.	 neurodegeneration)	has	been	a	 topic	of	




cells	 (RGC),	 bipolar	 cells,	 amacrine	 cells,	 horizontal	 cells	 and	 photoreceptor	 cells.	




the	 retina	 can	 be	 a	 result	 of	 several	 conditions,	 such	 as	 glaucoma,	 diabetic	
retinopathy,	age-related	macular	degeneration,	retinal	vascular	occlusions	or	retinitis	















fields,	 propagate	 action	 potentials	more	 quickly	 in	 the	 optic	 nerve	 and	 are	more	
sensitive	 to	 low-contrast	 stimuli.	 The	 small	 bistratified	 cells	 have	 unique	 roles	 in	
encoding	blue-yellow	colour	information.	Nonetheless,	these	major	types	of	RGCs	in	





their	 extensive	 energy	 requirements.	 Interestingly,	 compared	 to	 large	myelinated	
neurons	elsewhere	in	the	body,	the	axons	of	RGCs	are	not	myelinated	initially,	when	
they	 are	 situated	 within	 the	 retina,	 but	 only	 become	myelinated	 once	 they	 pass	
through	the	lamina	cribrosa.11	Normally,	a	myelinated	neuron	would	only	have	lost	
its	 myelin	 sheath	 only	 at	 the	 very	 peripheral	 end	 of	 its	 axon.	 This	 leads	 to	 an	
“impedance	 mismatch”	 in	 RGCs	 –	 all	 the	 more	 reason	 for	 a	 high	 metabolic	
requirement.11	 It	 can	 be	 observed	 that	 there	 are	 plenty	 of	 mitochondria-filled	





These	 unique	 structural	 features	 of	 RGCs	 increase	 their	 vulnerability	 to	










to	 remain	 viable.	 RGCs,	 however,	 are	 able	 to	 compensate	 by	 possessing	 a	 high	
antioxidant	 capacity	 (endogenous	 peroxidases).	 Even	 despite	 this	 being	 the	 case,	













displaced	 amacrine	 cells,	 astrocytes,	 microglia	 and	 vascular	 endothelial	 cells.	
Numerous	efforts	have	focused	on	developing	methods	to	reliably	distinguish	RGC	
from	the	others,	especially	displaced	amacrine	cells,	which	are	also	neurons.		
Traditional	histological	methods,	 such	as	 tissue	 staining	with	haematoxylin	
and	eosin	or	Nissl	are	still	used	for	general	tissue	assessment,	but	these	techniques	
largely	 cannot	 distinguish	 different	 cell	 types.20	 Since	 RGCs	 project	 to	 the	 brain,	
however,	a	useful	methodology	does	exist	 for	 identification	of	these	cells.	Here,	a	
tracer	molecule	or	dye	(e.g.	Fluorogold)21		is	injected	into	the	brain	of	a	test	animal	












labelling	procedure.	 Furthermore,	 this	method	avoids	 the	 risk	of	 inadvertent	RGC	
injury	prior	to	immunostaining.	Nevertheless,	this	approach	comes	with	drawbacks.	
Thy1,	 a	 cell	 surface	 protein,	 for	 instance,	 changes	 its	 expression	 following	 retinal	
damage,	 thus	 making	 it	 an	 unsuitable	 marker	 for	 studies	 on	 retinal	
neurodegeneration.20	There	is	also	a	general	inadequacy	in	these	markers,	compared	
to	Fluorogold	 retrograde	 labelling,	 in	detecting	 the	RGC	population	 in	 its	entirety.	
Despite	 this,	 recent	 studies	 have	 provided	 a	 number	 of	 novel	 and	 specific	 RGC	
markers	 which	 can	 be	 labelled	 on	 histological	 sections	 or	 whole-mounts.	 These	




Glaucoma	 refers	 to	 a	 group	 of	 ocular	 conditions	 united	 by	 a	 clinically	
characteristic	intraocular-pressure	associated	optic	neuropathy	with	accompanying	
loss	of	RGCs.30	It	is	estimated	that	glaucoma	will	affect	more	than	80	million	people	
worldwide	 by	 2020	 with	 at	 least	 up	 to	 8	 million	 of	 them	 becoming	 bilaterally	
blind.31,32	The	prevalence	of	glaucoma	correlates	highly	with	age,	affecting	over	1	in	
10	Black	people	at	80	years	of	age	and	1	in	50	Caucasians	between	40	–	60	years	of	
age.31,33-35	 There	 is	 no	 single	 clinical	 biomarker	 to	 determine	 the	 diagnosis	 of	
glaucoma,	but	its	presence	requires	evidence	of	retinal	nerve	fibre	layer	loss	(thinning	







with	 the	 pathogenic	 processes	 of	 glaucoma	 could	 be	 administered,	 either	
prophylactically	or	at	 the	time	of	diagnosis.	Here,	 the	clinical	 features,	pathogenic	







superior	 and	 inferior	 rim	of	 the	optic	 disc	 (vertical	 enlargement	of	 disc	 cup).	 This	





nasal	 step,	 arcuate	 scotoma,	 altitudinal	 scotoma	 and	 generalised	 depression.	 In	
relation	to	associated	high	IOP,	nasal	step	and	arcuate	defects	are	associated	with	
glaucoma	 related	 to	 elevated	 IOP,	 whereas	 paracentral	 scotomas	 are	 seen	more	
commonly	in	normal	tension	glaucoma.	Standard	automated	perimetry	and	optical	
coherence	tomography	of	the	retinal	nerve	fibre	layers	are	mainstay	investigations	









derived	 from	 a	 combination	 of	 both	 of	 these	 processes.	 A	 critical	 biophysical	
component	 for	 glaucomatous	 injury,	 deriving	 from	 both	 of	 these	 theories	 is	 the	
susceptibility	of	the	optic	nerve	head	and/or	the	retina	to	IOP-induced	forces.	The	
biomechanics	 of	 the	 eye,	 determined	 by	 its	 anatomy	 and	 tissue	 properties,	 are	
affected	 reciprocally	 by	 the	 IOP,	which	ultimately	 influences	both	blood	 flow	and	
cellular	responses	in	the	retina,	especially	at	the	optic	nerve	head.	Insults	at	the	optic	
nerve	 head	 likely	 initiate	 RGC	 degeneration	 and	 morphological	 changes,	 which	
translates	to	the	clinical	picture	of	glaucomatous	optic	neuropathy	with	visual	signs	
of	optic	disc	excavation	and	characteristic	visual	field	defects.44,45	The	“type”	of	insult	






as	 seen	 in	 categories	 of	 glaucoma	 that	 are	 associated	with	 elevated	 IOP,	 such	 as	
primary	open	angle	glaucoma,	angle-closure	glaucoma	or	secondary	glaucoma.	It	is	
proposed	that	 the	connective	tissue	that	comprises	 the	optic	nerve	head	 is	highly	




the	 actual	 location	 of	 the	 optic	 nerve	 head)	 provides	 an	 area	 where	 IOP-related	
stresses	are	particularly	concentrated.	Eventually,	morphological	deformations	due	
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to	 such	 stresses	 in	 this	 region	 cause	 axonal	 degeneration	 and	 RGC	 loss	
(neurodegeneration).46-48	
At	 the	molecular	 level,	 it	 has	 been	 hypothesized	 that	 physical	 ‘kinking’	 of	
tissue	 components	 in	 the	 optic	 nerve	 head	 due	 to	 elevated	 IOP	 causes	 disturbed	
axoplasmic	 flow	 of,	 for	 example,	 neurotrophic	 factors	 and	 other	 essential	
biomolecules.	It	is	also	thought	that	these	tissue	and	cellular	defamations	ultimately	




to	 subsequent	 tissue	 remodelling.50,51	 Additionally,	 metalloproteinases,	 major	




explain	 all	 observed	 clinical	 cases,	 however.	Ocular	hypertension	 (elevated	 IOP	at	
baseline	without	evidence	of	optic	nerve	damage),	for	example,	 is	more	prevalent	
than	actual	glaucoma,	meaning	that	not	all	incidences	of	elevated	pressure	convert	
to	 the	disease.54,55	 In	addition,	glaucoma	can	also	 result	 from	normal	 IOP	 (normal	
tension	glaucoma;	NTG).34	This	leads	to	the	second	hypothesis	for	the	mechanism	of	





The	 blood	 supply	 to	 the	 optic	 nerve	 head	 can	 be	 divided	 into	 four	 zones:	



















among	 other	 processes,	 the	 accumulation	 of	 reactive	 oxygen	 species.	 Reactive	
oxygen	 species	 are	 produced	 in	 mitochondria	 by	 physiological	 processes;	 at	 low	
levels	 these	 are	 crucial	 for	 cell	 signalling,	 however	 at	 high	 levels	 they	 lead	 to	 cell	
damage	or	death	via	a	variety	of	processes.53	Oxidative	stress,	which	is	defined	as	the	
accumulation	of	reactive	oxygen	species	at	pathological	levels,	has	been	postulated	
to	play	multiple	 roles	 in	 retinal	 tissue	destruction	 in	glaucoma	as	well	 as	 in	other	
neurodegenerative	 diseases,	 such	 as	 Huntington’s	 disease	 and	 Parkinson’s	
disease.38,40,41,53	Oxidative	damage	may	also	affect	vascular	auto-regulation	causing	
reductions	in	ocular	blood	flow	and	trabecular	meshwork	damage.	Furthermore,	it	
may	 activate	 apoptosis	 via	 both	 caspase-dependent	 and	 caspase-independent	
pathways.	 Oxidative	 stress	 also	 affects	 retinal	 glutamate-glutamine	 cycling	 by	
modifying	the	enzyme	glutamine	synthetase	and	causing	toxic	levels	of	glutamate	to	









via	 release	 from	 intracellular	 stores.	 The	 excessive	 accumulation	 of	 cytosolic	 Ca2+	
activates	a	number	of	enzymes	(e.g.	caspases),	and	signalling	pathways,	ultimately	
leading	 to	 cell	 death	 via	 apoptosis.	 Prolonged	 elevation	 of	 cytosolic	 Ca2+	 in	 the	


















factors	 in	 relation	 to	 perfusion	 abnormalities	 (cardiovascular	 disease,	 systemic	










agonists	and	carbonic	anhydrase	 inhibitors),	and	progressing,	 if	necessary	 to	 laser	
therapy	 (selective	 laser	 trabeculoplasty,	 peripheral	 iridotomy),	 filtration	 surgery	





have	been	noted.	The	general	 consensus,	however,	 for	 the	 initial	 IOP	 target	 for	a	
patient	 starting	 on	 treatment	 is	 about	 1/3	 of	 the	 patient’s	 initial	 recorded	 IOP.	
Despite	 this,	 target	 IOPs	 should	 be	 individualised	 on	 the	 basis	 of	 age,	 stage	 of	
glaucoma	and	the	patient’s	life	expectancy.		
Despite	 the	 recognition	 of	 IOP	 reduction	 in	 glaucoma	management,	 not	 all	
optic	nerve	damage	from	glaucoma	can	be	avoided	(or	prevented).	This	raises	the	
understanding	that	elevated	IOP	does	not	fully	account	for	the	pathophysiology	of	










our	 laboratory	 has	 previously	 demonstrated	 that	 experimentally	 induced	




(SAMe),	 a	 precursor	molecule	 in	 creatine	 synthesis,	 has	 resulted	 in	 restoration	of	
photoreceptor	function	in	a	rat	model	of	retinal	ischaemia,	whereby	this	restoration	
coincided	 with	 increase	 in	 creatine	 transporter	 (CRT-1)	 expression	 following	 the	









retina.72	 In	 studies	 on	 major	 neurodegenerative	 diseases	 (e.g.	 Parkinson’s	 and	
Alzheimer’s	disease),	creatine	has	been	shown	to	be	neuroprotective	both	in	culture	
and	animal	studies.73,74	It	has	also	been	shown	to	be	protective	in	various	neuronal	
injury	 models,	 such	 as	 NMDA-induced	 toxicity.	 It	 was	 further	 proven	 to	 provide	
positive	effects	to	neurons	 in	models	of	energetic	 failure	resulting	from	reversible	
and	 irreversible	 inhibitors	 of	 succinate-coenzyme	 Q	 reductase	 (also	 known	 as	
	 12	
respiratory	 chain	 II).75	 In	 models	 of	 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	
(MPTP),	where	the	neurotoxin	destroys	dopaminergic	neurons	in	the	substantia	nigra	
to	 cause	 symptoms	of	 Parkinson’s	disease,	 creatine	has	 shown	a	dose-dependent	
neuroprotective	 effect.76-78	 In	 transgenic	 mice	 models	 of	 amyotrophic	 lateral	
sclerosis,	creatine	administration	resulted	in	extension	of	survival,	improved	motor	
performance	and	reduction	 in	 loss	of	motor	neurons.79,80	Similar	results	were	also	
shown	 for	 transgenic	 mice	 models	 of	 Huntington’s	 disease,	 even	 when	




process	of	 transferring	a	phosphate	group	 to	creatine	 to	 form	phosphocreatine	 is	
catalysed	 by	 creatine	 kinase	 (CK),	 which	 exists	 in	 two	 isoforms:	 cytosolic	 CK	 and	
mitochondrial	CK	(Mi-CK).	Cytosolic	CK	is	a	heterodimeric	protein	which	consists	of	
two	 subunits:	 B	 (brain)	 type	 or	M	 (muscle)	 type.	 Three	 different	 isoenzymes	 can	
therefore	result	from	such	combination:	CK-MM,	CK-BB	and	CK-MB.	There	are	two	
tissue-specific	Mi-CK	isoenzymes,	termed	sarcomeric	Mi-CK	(found	in	striated	muscle)	
and	 ubiquitous	 Mi-CK	 (found	 in	 other	 tissues	 including	 neural	 tissue).	 Mi-CK,	 in	
contrast	to	the	dimeric	form	of	cytosolic	CK	isoenzymes,	forms	highly	symmetrical,	
cube-like	 octameric	 structures	 that	 peripherally	 bind	 to	 lipid	 membranes	 and	












acts	 as	 a	 regulatory	 enzyme	 to	 achieve	 equilibrium	 between	 creatine	 and	
phosphocreatine	 and,	 therefore,	 between	 ATP	 and	 ADP	 (Figure	 1.1).	 In	 this	 way,	
creatine	acts	as	a	cellular	energy	buffer.	Another	fraction	of	the	cytosolic	CK,	termed	
CK-g,	 is	 coupled	 to	 glycolytic	 enzymes	 and	 transfers	 phosphate	 groups	 from	 ATP	
produced	via	glycolysis	 to	creatine,	 forming	phosphocreatine.	Mi-CK,	on	the	other	
hand,	 interacts	 with	 the	 adenine	 nucleotide	 translocator	 (ANT)	 of	 the	 inner	
membrane	 of	mitochondria	 to	 form	 a	 transient	 dynamic	 channel	 at	 the	 so-called	
‘mitochondrial	 energy	 transfer	 contact	 sites.’	 ATP	 generated	 by	 oxidative	
phosphorylation	 is	 transported	 through	 the	 ANT	 in	 exchange	 for	 ADP	 and	 is	
transphosphorylated	 by	Mi-CK	 to	 produce	 phosphocreatine.	 Phosphocreatine	 and	






creatine	 and	 phosphocreatine.	 This	 system	 is	 crucial	 for	 cells	 with	 high	 energy	

























result,	 glutamate-induced	 neuronal	 excitotoxicity	 (via	 excessive	 intracellular	 Ca2+)	
may	be	prevented.91,93-96	
Creatine	 supplementation	 may	 also	 prevent	 apoptosis	 by	 inhibiting	 the	
opening	of	mitochondrial	permeability	pore	through	the	action	of	Mi-CK.73,85,91,97	The	
octameric	Mi-CK	that	is	located	within	the	intermembrane	space	of	the	mitochondria	
associates	 with	 the	 mitochondrial	 permeability	 pore	 complex	 and	 results	 in	 its	
closure	or	 ‘stabilization.’	When	Mi-CK	 is	 converted	 to	 its	dimeric	 form,	which	 can	
happen	in	the	presence	of	free	radicals,	its	association	with	the	permeability	pore	is	
weaker	 and	 this	 leads	 to	 opening	 of	 the	 pore.	 Opening	 of	 the	 mitochondrial	
permeability	pore	allows	release	of	apoptosis-stimulating	factors	and	ultimately	cell	
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Parkinson’s	 disease	 in	 1999.77	 It	 was	 shown	 that	 intraperitoneal	 injection	 of	
neurotoxin	MPTP,	which	 blocks	 complex	 I	 of	 the	mitochondrial	 respiratory	 chain,	
depletes	striatal	ATP	concentrations	and	causes	neuronal	damage,	but	pre-treatment	
with	1%	creatine	for	2	weeks	almost	completely	abolished	the	deleterious	effects.	
Interestingly,	 this	 protective	 effect	 of	 creatine	 was	 shown	 to	 be	 enhanced	 in	
combination	with	cyclooxygenase-2	inhibitor	rofecoxib.78	In	a	later	study	of	chronic	




inhibitors	 3-nitropropionic	 acid	 or	 malonate	 to	 rats	 led	 to	 behavioural	 and	
neuropathological	 features	 resembling	 human	 Huntington’s	 disease.	 When	 oral	
creatine	was	administered	before	treatment,	the	treated	rats	were	associated	with	
lower	lesion	volume	and	higher	brain	ATP	and	phosphocreatine	levels.82	In	transgenic	
mouse	 models	 of	 Huntington’s	 disease,	 prophylactic	 creatine	 administration	 also	
provided	significant	protection	by	evidence	of	improvement	in	motor	performance	
and	higher	overall	survival.81	
In	 amyotrophic	 lateral	 sclerosis,	 a	 standard	 rodent	model	 uses	 transgenic	
mice	 carrying	 multiple	 copies	 of	 the	 human	 SOD1G93A	 gene,	 resulting	 in	 early	
mitochondrial	swelling,	vacuolization	and	altered	respiratory	chain	enzyme	activities.	
These	 changes	 correspond	 to	 similar	mitochondrial	 abnormalities	observed	 in	 the	
post-mortem	 spinal	 cords	 of	 amyotrophic	 lateral	 sclerosis	 patients.98,99	 In	 these	
models,	 two	 separate	 studies	 have	 reported	 that	 1-2%	 of	 creatine,	 when	
administered	within	1-2	months	of	birth,	resulted	in	a	dose-dependent	rise	in	survival,	
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reduction	 of	 neuronal	 death,	 as	 well	 as	 a	 delay	 in	 the	 manifestation	 of	 motor	
abnormalities,	when	compared	to	the	placebo.79,80	The	combination	of	minocycline	
(tetracycline	antibiotic)	and	COX-2	inhibitors	also	produced	additive	neuroprotective	
effects.100	 Conversely,	 a	 separate	 study,	 in	 which	 common	 methodological	
confounders	 in	previously	published	successful	murine	SOD-trials	were	controlled,	
was	 only	 able	 to	 report	 a	 non-significant	 survival	 extension	 of	 less	 than	 1%	 in	
creatine-treated	animals.101	
1.2.4 Clinical	trials	of	creatine	neuroprotection	
Given	 the	 success	 in	 animal	 models	 in	 providing	 evidence	 for	 creatine	
neuroprotection,	 several	 human	 trials	 have	 been	 performed	 for	 major	
neurodegenerative	diseases.	A	randomized	placebo-controlled	clinical	trial	 in	2008	
found	no	difference	 in	disease	progression	 in	60	Parkinson’s	disease	patients	who	
were	 supplemented	 with	 creatine	 over	 2	 years.102	 In	 the	 same	 year,	 a	 futility-
monitored,	 randomized,	 controlled	 trial	 investigating	 200	 early-onset	 Parkinson’s	
disease	patients	concluded	that	creatine	could	not	be	rejected	as	 futile	 in	slowing	
disease	progression	and	that	it	therefore	showed	potential	for	success	in	later	stage	
trials.103	A	meta-analysis	of	 two	Phase	 II	 trials	 revealed	no	benefit	 for	 creatine	on	
improving	motor	function	in	Parkinson’s	disease	patients,	but	did	report	that	there	
was	 perhaps	 insufficient	 data	 to	 draw	 any	 firm	 conclusions.104	 Interestingly,	 a	
separate	double-blinded	Phase	 III	 randomized	controlled	 trial	 that	started	 in	2007	
showed	 that	 creatine	 may	 even	 result	 in	 more	 rapid	 disease	 progression	 in	
Parkinson’s	 disease	 patients.105	 A	 recent	 clinical	 trial,	 conversely,	 investigated	 the	
effect	of	both	creatine	and	coenzyme	Q10,	in	combination,	on	motor	and	cognitive	
functioning	and	showed	that,	despite	the	fact	that	there	was	no	significant	difference	




















it	 is	difficult	 to	predict	 the	actual	 timing	of	diagnosis,	 commencement	of	 creatine	
supplementation	 in	 human	 patients	 can	 therefore	 only	 be	 administered	 when	 a	
diagnosis	 is	 made.	 This	 is	 true	 for	 sporadic	 neurodegenerative	 diseases	 such	 as	
Parkinson’s	disease	and	amyotrophic	lateral	sclerosis	where	creatine	administration	
at	 the	 time	 of	 diagnosis	may	well	 be	 too	 late	 for	 any	 neuroprotective	 effects	 to	
surface.110	In	contrast,	Rosas	and	colleagues	in	2014	found	that	Huntington’s	disease	
carriers	(patients	in	the	premanifest	state)	receiving	creatine	had	significantly	slower	
rates	 of	 cortical	 thinning	 compared	 to	 placebo-treated	 individuals,	 suggesting	 a	
potential	beneficial	effect	from	creatine	on	prodromal	progression..109	Although	no	




Indeed,	 if	 creatine	was	 to	work	 in	 a	 dose-dependent	 fashion	 to	 protect	 neuronal	
tissue,	a	higher	dose	of	creatine	could	be	provided	to	patients,	especially	taking	into	





pathological	 mechanisms	 (e.g.	 energy	 failure,	 oxidative	 stress	 and	 mitochondrial	
dysfunction)	are	still	in	their	active	state.		
Creatine	 has	 been	 associated	 with	 increase	 in	 nausea	 and	 diarrhoea	 when	
administered	 orally,	 however	 with	 no	 significant	 clinical	 or	 laboratory	
complications.109	 Safety	 concerns	 regarding	 adverse	 effects	 of	 creatine	 on	 renal	
function,	especially	if	taken	at	high	doses,	remain	hypothetical.	Data	from	multiple	
randomized	 controlled	 trials	 for	 neurodegenerative	 diseases	 as	 well	 as	 clinical	
research	fielding	other	areas	of	medicine	(e.g.	myopathies,	psychiatric	and	cardiac	
disease)	have	demonstrated	that	 there	 is	a	consistently	safe	profile	 for	 the	use	of	
externally	 applied	 creatine.	 For	 example,	 creatine	 remains	well	 tolerated	 even	 in	








elsewhere,	 in	 which	 creatine	 has	 shown	 positive	 effects.	 Creatine	 can	 be	
administered	orally	and	has	a	known	good	safety	profile.	It	would	therefore	stand	as	






issues	 remain	 concerning	 its	 systemic	 uptake	 and	 whether	 hyperglycemic	
microvascular	complications	may	result	from	its	application.		
In	the	first	study	in	this	thesis,	an	immunohistochemical	characterisation	of	the	
effects	 to	 a	 selection	 of	 specific	 antigenic	 markers	 was	 undertaken	 in	 a	 well-
characterized	 animal	 model	 of	 RGC	 injury.	 This	 study	 was	 to	 provide	 a	 greater	




toxicity.	 This	 work	 was	 supplemented	 by	 investigating	 the	 protective	 efficacy	 of	
creatine	for	cells	in	mixed	retinal	cultures	consisting	of	dissociated	neurons	and	glia	
which	were	subjected	to	metabolic	compromise.	Finally,	as	a	result	of	the	findings	







The	 inner	 rather	 than	 the	 outer	 retina	 constitutes	 the	 major	 target	 of	
degenerative	diseases	 to	 retinal	 neurons	other	 than	photoreceptors.	 In	 the	main,	
retinal	 neurons	 are	 particularly	 susceptible	 to	 vascular	 insults,	 but	 of	 these,	 the	
retinal	ganglion	cells	(RGCs)	are	of	particular	interest	in	glaucoma.	Uniquely,	among	





their	 location	 in	 the	 ganglion	 cell	 layer	 with	 an	 approximately	 numerically	 equal	
population	of	displaced	amacrine	cells;	furthermore,	a	small	proportion	have	their	













to	 98%	 of	 RGCs	 are	 labelled	 in	 rodents.	 However,	 in	 order	 to	 gain	 access	 to	 the	
superior	 colliculus,	 complex	 surgery	 and	 fine	 tissue	 manipulation	 are	 necessary.	
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These	 could	 either	 risk	 damaging	 the	 brain,	 leading	 to	 significant	 cerebral	
inflammation,	or	insufficiently	label	RGCs	if	techniques	were	not	optimal.22,114	
An	 alternate	 approach	 to	 RGC	 identification	 is	 via	 immunohistochemical	
detection	 of	 proteins	 or	 nucleic	 acids	 specific	 to	 these	 cells.	 For	 instance,	 in	 the	
context	 of	 the	 physiological	 retina,	 Thy1	 has	 been	 described	 as	 an	 RGC-specific	
antigen.115,116	 This	 is	 of	 use	 for	 detection	of	 RGCs	 in	 control	 tissues,	 however	 the	
pattern	 of	 Thy1	 expression	 changes	 after	 retinal	 damage,	with	 this	 antigen	 being	
subsequently	detected	 in	other	 local	 cells	 to	 a	 small	 degree,	 such	as	Müller	 cells,	
amacrine	cells	or	bipolar	cells.117	Labelling	of	Bex1/2	provides	visualisation	of	both	
RGC	 bodies	 and	 their	 axons,	 allowing	 good	morphological	 use,	 but	would	 not	 be	
suitable	for	quantification	purposes.118,119		
For	quantification	of	RGC	loss	or	damage	in	diseased	retinas	and	relevant	model	
systems,	 there	 is,	 therefore,	 a	 great	 need	 for	 identification	 of	 a	 suitable,	 specific	
marker	 of	 these	 cells.	 Immunohistochemical	 labelling	 of	 RGCs	 in	 retinal	 whole-
mounts	rather	than	sections	is	preferable	as	this	method	covers	the	distribution	of	
these	 cells	 throughout	 the	 retina,	 rather	 than	 in	 just	 a	 single	 dimension.	
Quantification	 of	 RGCs	 on	 whole-mount	 preparations	 therefore	 provides	 higher	
reliability	 and	 accuracy	 in	 estimating	 true	 numbers	 of	 these	 cells.	 Several	 RGC	
markers	have	been	proposed	as	reliable	RGC	markers	on	whole-mounts,	 including	
Brn3a,	 γ-synuclein	 and	 RNA	 binding	 protein	 with	 multiple	 splicing	
(RBPMS).23,25,28,29,118,120	 Calretinin	 also	 labels	 cells	 in	 the	 retinal	 ganglion	 layer,	
although	it	also	labels	positive	for	cells	in	the	nuclear	layer.121	Despite	the	availability	
of	 all	 of	 these	potential	RGC	marker	antigens,	 there	 is	 a	paucity	of	data	available	
which	 compares	 their	 labelling	 efficiency	 and	 their	 use	 in	 quantifying	 cell	 loss,	
especially	 in	 rodent	 models.	 Our	 study	 aimed,	 therefore,	 to	 employ	 a	 spatio-











the	 ARVO	 Statement	 for	 the	 Use	 of	 Animals	 in	 Ophthalmic	 and	 Vision	 Research.	
Animals	were	housed	with	standard	food	and	water	provided	ad	libitum.	The	light	
was	turned	on	at	7	AM	and	turned	off	at	7	PM.		Animals	were	divided	into	groups	




Intravitreal	 injection	 of	 NMDA	was	 used	 to	 induce	 RGC	 loss	 in	 rat	 retinas	
according	to	previously	described	method.122-124	Briefly,	9-	to	10-week-old	Sprague-





Some	 animals	 were	 randomized	 to	 a	 control	 group	 where	 NMDA	 was	 not	








3%	 normal	 horse	 serum.	 Standard	 immunohistochemical	 procedures	 were	





normal	horse	 serum	overnight	at	4˚C	and	 then	secondary	antibody	 for	3	hours	at	
room	 temperature.	 Tissue	 preparations	 were	 then	 washed	 in	 PBS	 before	 being	























2.1).	 For	 calretinin	 and	 γ-synuclein	 counts,	 the	 central	 areas	were	omitted	 as	 the	




images	of	 each	RGC	 label	used	and	 the	 size	 and	morphology	of	 cells	 included	 for	














in	 the	 areas	 adjacent	 to	 optic	 nerve	 that	 prevents	 adequate	 retinal	 ganglion	 cell	






















(untreated	 control	 and	 8-hour,	 24-hour,	 3-day	 and	 7-day	 post-NMDA	 injection),	
expressed	 as	 percentage	 of	 remaining	 immunoreactivity	 with	 regards	 to	 the	
untreated	control.	Data	for	all	other	the	figures	are	instead	expressed	in	raw	counts	












	 CONTROL	 8-hour	 24-hour	 3-day	 7-day	












































Quantification	 revealed	 that	Brn3a-positive	cells	at	all	analysed	 times	after	
NMDA	treatment	were	significantly	reduced	when	compared	with	control	retinas	(Fig.	
2.4f;	P	=	0.001).	Similarly,	Brn3a	counts	at	the	8-hour	time-point	were	significantly	














and	 24	 hours	 post-NMDA,	multiple	 ‘shrunken’	 RBPMS-positive	 cells	 could	 also	 be	
noted,	as	was	the	case	with	Brn3a.	Although	the	raw	counts	differed	from	counts	for	


















(a)	 Brn3a-positive	 and	 (b)	 RBPMS-positive	 cells	 plotted	 versus	 time	 after	 NMDA	























Figure	 2.8.	 Histological	 cross-section	of	 central	 retina	 in	 eyes	 treated	with	NMDA	
injection.	 Retinal	 staining	 with	 anti-RBPMS	 showing	 progressive	 loss	 of	 retinal	
ganglion	cells	for	control	eyes	and	eyes	harvested	at	8	hours,	24	hours,	3	days	and	7	




When	 assessing	 γ-synuclein-positive	 cells,	 it	was	 obvious	 that	 there	was	 a	
similar	decline	in	numbers	as	seen	with	RBPMS,	up	to	8	hours	after	NMDA	injection;	

















be	 statistically	 significant	 from	 24	 hours	 (Fig.	 2.12f;	 P	=	 0.02	 for	 counts	 between	
control	and	24-hour	NMDA,	P	=	0.001	for	counts	between	control	and	3-day	and	7-




























injection.	Retinal	 staining	with	anti-γ-synuclein	 showing	progressive	 loss	of	 retinal	
ganglion	cells	for	control	eyes	and	eyes	harvested	at	8	hours,	24	hours,	3	days	and	7	













injection.	 Retinal	 staining	 with	 anti-calretinin	 showing	 progressive	 loss	 of	 retinal	
ganglion	cells	for	control	eyes	and	eyes	harvested	at	8	hours,	24	hours,	3	days	and	7	






represents	 an	 RGC	 injury	 model	 that	 is	 widely	 used	 for	 the	 study	 of	 retinal	
neurodegeneration.	NMDA	is	a	non-metabolisable	analogue	of	the	major	excitatory	
retinal	neurotransmitter,	glutamate.	The	application	of	NMDA	to	a	nervous	tissue	will	
therefore	 persistently	 activate	 systems	 designed	 to	 be	 excited	 under	 normal	
circumstances	by	glutamate;	it	will	therefore	“excite	a	neuron	to	death,”	hence	the	
term	 excitotoxicity.	 NMDA	 stimulates	 a	 specific	 class	 of	 ionotropic	 glutamate	
receptors,	the	NMDA-type	receptors,	leading	to	opening	of	ion	channels	which	are	
selective	 for	calcium	and	sodium,	and,	 to	a	 lesser	extent,	potassium.	Cation	entry	
after	 NMDA	 receptor	 stimulation	 activates	 a	 wide	 range	 of	 cellular	 processes	
including	 opening	 of	 intracellular	 calcium	 stores,	 activation	 of	 proteases,	
mitochondrial	 dysfunction,	 osmotic	 shock,	 energy	 depletion	 and	 ultimately,	 cell	
death,	either	by	necrosis	–	often	accompanied	by	cell	lysis	-	or	apoptosis.	Within	the	
retina,	NMDA-type	glutamate	receptors	are	predominantly	expressed	on	RGCs	and	




“cell	death”.	 It	 is	both	difficult	to	define	at	what	point	 in	the	demise	of	a	cell	that	
“death”	 will	 occur	 and	 difficult	 to	 show,	 in	 practical	 terms,	 that	 this	 point	 has	
occurred.	In	terms	of	the	former,	it	can	be	stated	that	a	cell	is	no	longer	able	to	survive	
when	central	 cellular	 functions	are	 irretrievably	 lost;	 therefore,	 it	 can	presumably	
also	be	stated	that	when	a	cell	has	passed	such	a	point,	it	is	dead.	How	do	we	detect	
when	 a	 cell	 has	 passed	 this	 point?	We	 can	 assay	 for	 a	 specific	 function,	 such	 as	
cessation	of	production	of	a	specific	or	key	cellular	mRNA	species.115	However,	it	can	
be	argued	that	such	an	action	is	induced	quickly	in	stressed	RGCs	and	is	either	not	




protein	 markers,	 which	 are	 specific	 to	 these	 cells	 in	 their	 live	 and	 normally	
functioning	state,	in	situations	when	we	know	these	cells	are	damaged	or	lost.	The	
issue	here	is	that	we	do	not	know	how	a	particular	antigen	will	respond	to	injury	and	







In	 this	 study,	 four	 different	 markers	 for	 RGCs	 were	 compared:	 Brn3a,	 γ-
synuclein,	 calretinin	 and	 RBPMS.	 The	 different	 RGC	 antigen	 markers	 examined	
represent	 proteins	 with	 very	 different	 functions.	 It	 was	 interesting	 to	 determine	
whether	 these	 markers	 responded	 differently	 to	 injury	 because	 of	 their	 diverse	
functioning,	or	in	a	similar	way	to	the	insult	because	they	are	all	expressed	by	RGCs.	
Of	the	protein	markers	analysed,	Brn3a	is	a	transcription	factor,	a	member	of	POU4f	
transcription	 family,	 of	 which	 its	 expression	 levels	 likely	 reflect	 the	 physiological	
status	of	RGC.	RBPMS	is	a	RNA-binding	protein,	a	member	of	the	RNA	recognition	
motif	family,	involved	in	the	regulation	of	gene	expression	at	the	post-transcriptional	
level,	 including	 pre-mRNA-processing,	 RNA	 stability,	 transport,	 localization	 and	
translational	 regulation.	 γ-synuclein	 and	 calretinin	 are	 cytoplasmic	 proteins	 that	
reflect	 more	 the	 actual	 physiology	 of	 the	 cell.23,28	 γ-synuclein	 is	 a	 small	 natively	
unfolded	 protein	 localized	 adjacent	 to	 the	 RGC	 nuclear	 marker	 Brn3a	 at	 the	
perinuclear	 area	 as	 well	 as	 in	 the	 axons.25	 Calretinin,	 on	 the	 other	 hand,	 is	 a	




The	 use	 of	 immunofluorescence	 on	 whole-mounts	 as	 a	 means	 of	
quantification	 to	describe	 the	 temporal	 characterisation	of	 RGC	 loss	 after	NMDA-
induced	 retinal	 excitotoxicity	 is	 relatively	 new.	 Some	 of	 the	markers	 used	 in	 the	
present	study	have,	however,	been	used	to	label	RGCs	after	optic	nerve	crush	and	







Kwong	and	 colleagues	have	demonstrated	 that	 the	 greatest	 occurrence	of	












would	 be	 expected	 that	 the	 counts	 would	 plateau	 at	 a	 value	 reflective	 of	 the	









with	 the	 data	 of	 Kwong	 and	 colleagues,	 showing	 that	 maximal	 apoptosis	 occurs	
within	the	first	24	hours	of	NMDA	exposure	and	then	tails	off	after	this.124		
Labelling	for	both	Brn3a	and	RBPMS	indicated	similar	overall	loss	of	about	85%	
of	 immunoreactivity	 by	 the	 end	 of	 our	 experiment	 (7	 days).	 This	 figure	 is	 slightly	
greater	than	that	reported	in	the	literature	for	NMDA-induced	RGC	loss	(about	80%)	
quantified	 via	 histological	 and	 retrograde	 labelling	 methods.128,129	 In	 optic	 nerve	
crush	and	transection	models,	both	Brn3a	and	RBPMS	are	reduced	to	15-20%	at	7-9	
days	post-injury.28,136	In	retinal	ischaemia	models	via	high	intraocular	pressure,	level	















this	 would	 explain	 the	 difference	 in	 rate	 of	 decline	 in	 calretinin-positive	 cells	
compared	to	Brn3a-,	RBPMS-,	and	γ-synuclein-positive	cells	from	NMDA	toxicity.		
	 45	
	 γ-synuclein	 is	 a	 protein	 with	 an	 unknown	 function	 which	 is	 expressed	
throughout	RGC	cytoplasm	and	axons.	There	is	suggestion	that	it	may	be	involved	in	
microtubule	 regulation	 of	 the	 cell	 cytoskeleton.141	 Although	 in	 human	 eyes,	 γ-
synuclein	was	noted	to	predominantly	label	RGCs,25	it	has	also	been	observed	to	stain	
the	 inner	nuclear	 layer	 in	 rats,	 suggesting	 its	presence	 in	amacrine	cells.142	 In	our	
study,	however,	γ-synuclein	stained	cells	in	the	ganglion	cell	layer	as	well	as	a	number	
of	cells	in	the	outer	region	of	the	inner	nuclear	layer	which	resemble	horizontal	cells.	
γ-synuclein	 in	 the	 ganglion	 cell	 layer	was	 observed	 to	 co-label	with	 Brn3a,	which	
accounts	for	92	–	96%	of	FluoroGold-labeled	RGCs	in	rodents.25,28	As	we	have	also	
applied	similar	inclusion	criteria	as	for	calretinin,	we	did	not	include	smaller	cells	in	
the	 ganglion	 cell	 layer	 in	 our	 quantification;	 this,	 thus,	 provided	 us	 with	 a	 lower	
overall	 absolute	 count.	We	 showed	 that	 γ-synuclein	 declined	 at	 a	 similar	 rate	 to	
Brn3a	 and	 RBPMS,	 but	 with	 a	 much	 lower	 overall	 loss	 with	 an	 average	 of	 40%	
remaining	immunoreactivity	at	7	days	after	NMDA	treatment.	This	is	about	twice	the	
percentage	 of	 RGC	 survival	 (quantified	 via	 histological	 and	 retrograde	 labelling	
methods)	observed	from	previous	NMDA	treatment	with	an	equivalent	dose.128,129	
This	could	be	due	to	the	antigen	being	a	structural	protein	which	may	remain	in	situ	
even	 after	 cell	 death.	 This	may	 be	 unlikely	 as	 NMDA-induced	 retinal	 toxicity	was	
shown	to	cause	cell	death	via	apoptosis,	in	which	case	it	would	be	expected	that	there	
would	not	be	any	accumulation	of	 cellular	debris,	 provided	 that	 timely	 functional	
phagocytosis	 occurs.126,143	 On	 the	 other	 hand,	 the	 end-point	 of	 the	 remaining	 γ-
synuclein	 in	 our	 study	 may	 reflect	 loss	 of	 one	 population	 cells,	 as	 well	 as	 new	
expression	in	surviving	cells.	It	is	unknown	whether	γ-synuclein	is	newly	expressed	in	
tissues	 undergoing	 excitotoxic	 stress,	 but	 γ-synuclein	 has	 been	 shown	 to	 be	
overexpressed	 in	 cancer	 cells,	which	we	know	have	 intrinsic	oxidative	 stress	 from	
oncogenic	stimulation.144,145	If	this	is	the	case,	the	level	of	γ-synuclein	may	reflect	a	
dynamic	equilibrium	between	cell	loss	and	new	antigen	expression,	which	is	also	in	








of	 cell	 loss	was	 similar	 to	each	other.	Nevertheless,	quantification	of	RGC	 loss	 via	
counting	of	either	of	these	two	antigenic	markers	may	be	overestimated	due	to	their	
being	transcription	factors	and	thus	not	necessarily	reflecting	true	cell	loss.	On	the	
other	hand,	 γ-synuclein	 showed	a	 similar	 rate	of	 cell	 loss,	but	with	a	 less	marked	
overall	end-point,	which	may	either	be	an	effect	of	the	antigen	remaining	after	cell	
death	 or	 the	 dynamic	 equilibrium	 of	 cell	 loss	 versus	 new	 antigen	 expression	 in	
surviving	cells.	Calretinin	did	not	reflect	the	rate	of	cell	loss	that	has	been	reported	
and,	additionally,	is	not	specific	to	RGCs.	It	is,	therefore,	not	appropriate	for	calretinin	
to	be	used	 for	quantification	of	RGC	 loss.	Amongst	all	 tested	antigens,	Brn3a	and	

















Because	of	 the	relative	 length	of	 these	axons	and	the	 fact	 that	 they	 lack	a	myelin	
sheath	until	they	are	into	the	optic	nerve,	RGCs	have	an	increased	vulnerability	to	
any	local	mechanical,	vascular	or	metabolic	perturbation,	particularly	in	the	retina	or	
optic	nerve	head.	Thus,	damage	 to	or	death	of	 these	cells	 is	observed	 in	multiple	
blinding	retinal	conditions,	for	example,	glaucoma,	diabetic	retinopathy	and	ischemic	
optic	neuropathy.19		
The	 retinal	 degenerating	 condition,	 glaucoma,	 has	 known	 similarities	 with	
neurodegenerative	 conditions	 elsewhere	 in	 the	 central	 nervous	 system.	 At	 the	




these	mechanisms	may	 be	 via	mechanical	 or	 vascular	 injuries,	which	manifest	 as	
trauma	and	ischaemia/hypoxia,	respectively.	Often,	the	end	result	of	such	insults	is	
cellular	 energy	 failure,	 and	 this,	 itself,	 often	 leads	 to	 further	 oxidative	 and	
mitochondrial	damage.4	 It	would	 therefore	be	 ideal	 if	 there	were	agents	available	









anti-oxidant	 and	 a	 component	 of	 the	mitochondrial	 respiratory	 chain	 that	 carries	
electrons	 from	 complexes	 I	 and	 II	 to	 complex	 III,	 moreover,	 was	 shown	 to	 be	
neuroprotective	in	animal	models	of	Huntington’s	disease	and	Parkinson’s	disease,	
as	well	as	in	a	glaucoma	model	generated	by	elevating	intraocular	pressure	(IOP).148-
150	 It	 is	 interesting	 to	 also	 note	 that	 short-term	 hyperglycaemia	 and	 intraocular	
administration	 of	 glucose	 have	 also	 been	 shown	 to	 attenuate	 ischaemic	 retinal	
injury.112	Recently,	our	laboratory	has	demonstrated	significant	RGC	protection	via	
subconjunctival	 glucose	 administration	 in	 a	 rat	 model	 of	 acute	 elevated	 IOP.68	




treatment	 of	 major	 neurodegenerative	 disorders.	 Experimental	 testing	 of	 this	
compound	has	shown	a	degree	of	neuroprotection	in	both	in	vitro	and	in	vivo	animal	
models.74,91	 Although	 results	 so	 far	 have	 not	 supported	 the	 presence	 of	 any	



























This	 study	 was	 approved	 by	 the	 Animal	 Ethics	 Committees	 of	 SA	
Pathology/Central	Adelaide	Local	Health	Network	and	The	University	of	Adelaide	and	
conformed	to	both	the	Australian	Code	of	Practice	for	the	Care	and	Use	of	Animals	
for	 Scientific	 Purposes	 (2013)	 and	 the	 Association	 for	 Research	 in	 Vision	 and	
Ophthalmology	Statement	for	The	Use	Of	Animals	In	Ophthalmic	And	Vision	Research.	
All	 animals	 were	 obtained	 from	 the	 University	 of	 Adelaide,	 South	 Australia.	 For	





Rat	 retinal	 cell	 cultures	 comprising	 glia,	 photoreceptors	 and	neurons	were	
prepared	 from	 the	 pups	 via	 a	 trypsin-	 and	mechanical-digest	 procedure.151	 After	
tissue	 dissociation,	 cells	 were	 dispensed	 onto	 13	mm	 diameter	 borosilicate	 glass	
coverslips	 coated	 previously	 with	 poly-L-lysine	 (5	 µg/mL,	 15	 minutes)	 in	 24-well	
culture	 plates	 for	 immunocytochemical,	 fluorescent	 dye-labelling,	 or	 apoptotic	









10%	 (w/v)	 neutral-buffered	 formalin	 in	 0.1M	 phosphate	 buffer,	 pH	 7.4	 (NBF)	 for	
immunocytochemical	analysis.		
Animal	Models	of	Retinal	Ischaemia	and	Excitotoxicity	








to	 120	mmHg,	 which	 rendered	 the	 retina	 ischaemic.	 This	 was	maintained	 for	 75	
minutes.	All	rats	were	killed	at	seven	days	following	retinal	ischaemia	and	their	eyes	
removed	for	RGC	quantification.		
To	 establish	 excitotoxicity,	 the	 left	 eyes	 of	 all	 rats	 were	 subjected	 to	
intravitreal	 injections	 (using	 a	 32-gauge	 needle)	 of	 10	 nmol	 of	 NMDA,	 under	
observation	with	a	dissecting	microscope;	seven	days	following	NMDA	exposure	all	






performed	 in	both	 injured	and	control	eyes	before	 ischaemia	(baseline)	and	three	
and	 seven	 days	 after	 reperfusion.	 Rats	 were	 dark-adapted	 overnight	 and	
anaesthetized	briefly	with	an	intraperitoneal	injection	of	ketamine	(100	mg/kg)	and	
xylazine	 (10	 mg/kg).	 Pupils	 were	 dilated	 with	 1%	 tropicamide.	 Eyes	 were	
anaesthetised	with	0.04%	oxybuprocaine	hydrochloride.	Poly	Gel®	lubricating	eye	gel	















permeabilized	 with	 PBS	 containing	 0.1%	 Triton	 X-100	 (PBST-0.1%),	 followed	 by	
further	washing	in	PBS	and	then	blocking	in	PBS	containing	3%	normal	horse	serum	
(PBS-HS).	 Anti-calretinin	 (Molecular	 Probes;	 mouse)	 and	 anti-GABA	 (Molecular	
Probes;	rabbit)	antibodies,	diluted	in	PBS-HS	at	concentrations	of	1:1000	each,	were	
applied	overnight	at	room	temperature,	after	which,	coverslips	were	washed	in	PBS	





For	 in	 vivo	 experiments,	 all	 rats	were	 killed	 by	 transcardial	 perfusion	with	
physiological	saline	and	eyes	were	dissected	and	fixed	with	NBF	for	24	hours	at	room	
temperature.	 For	 tissue	 sectioning,	 whole	 eyes	 with	 optic	 nerve	 attached	 were	




10mM	 sodium	 citrate	 buffer	 (10mM	 tri-sodium	 citrate	 dihydrate	 in	 H2O;	 pH	 6.0).	
Tissue	 sections	 were	 then	 blocked	 in	 PBS-HS,	 incubated	 overnight	 at	 room	
temperature	in	anti-Brn3a	(1:3000	dilution	in	PBS-HS)	and	anti-γ-synuclein	(1:1000	
dilution	 in	 PBS-HS)	 primary	 antibodies,	 followed	 by	 consecutive	 incubations	 with	
biotinylated	 secondary	 antibody	 and	 streptavidin-peroxidase	 conjugate.	 Colour	
development	was	achieved	using	3’,3’-diaminobenzidine	plus	H2O2.	Sections	were	
counterstained	with	haematoxylin,	dehydrated	and	mounted.	Specificity	of	antibody	
staining	was	confirmed	by	 incubating	adjacent	 sections	 in	 the	absence	of	primary	
antibody.		
	 53	





day,	 whole-mounts	 were	 incubated	 with	 secondary	 anti-goat	 Alexa	 Fluor	 594	















washed	 in	 PBS.	 The	 retinal	 whole-mounts	 were	 then	 permeabilised	 with	 PBS	
containing	3%	triton	X-100	for	30	minutes,	treated	with	proteinase	K	(Sigma	Aldrich,	











incubations	of	 cells	with	 creatine	pre-treatment	 (24	hours	of	5	mM	creatine)	 and	
controls	(standard	medium)	were	performed	as	described	above	in	our	culture	model	
except	that	cultures	were	also	incubated	with	H2O2	substrates	simultaneously	with	







BMG	 Labtech,	 Mornington,	 Victoria,	 Australia).	 For	 quantification,	 luminescence	




from	 Sigma-Aldrich	 Chemical	 Company	was	 used.	 Cell	 samples	 were	 obtained	 by	
removing	culture	medium	and	extracting	cellular	contents,	 including	ATP,	 into	hot	



































rat	 retinal	 cultures	 (Figure	 3.2).	 This	 was	 measured	 by	 quantifying	 changes	 in	
neuronal	 labelling	as	detailed	 in	 the	Methods	 section.	When	 treated	with	 sodium	








relative	 to	 calretinin-positive	 neurons.	 Pre-treatment	 with	 creatine	 led	 to	 a	






Figure	3.1.	 Effect	of	24	hours	of	 creatine	 (0.5,	1.0	and	5.0	mM)	pre-treatment	on	
calretinin-immunoreactive	 and	 GABA-immunoreactive	 cells	 in	 rat	 retinal	 cultures,	






















































5.0	 mM	 creatine)	 and	 GABA-immunoreactive	 neurons	 (5.0	 mM	 creatine).	 No	
significant	difference	was	detected	in	neuron	survival	after	treatment	with	different	
creatine	concentrations	in	the	absence	of	sodium	azide.	*P	<	0.01	by	one-way	ANOVA	




Treatment	 for	 24	 hours	 with	 1	 mM	 sodium	 azide	 induced	 an	 increase	 in	
detectable	 TUNEL-positive	 cell	 nuclei	 in	 retinal	 cultures	 (Figure	 3.4).	 Concurrent	




Figure	 3.4.	 Sodium	 azide	 (1	mM)	 24-hour	 treatment	 in	 rat	 retinal	 cultures	 led	 to	
increased	TUNEL	labelling.	Concurrent	incubations	with	creatine	(0.5	mM	and	5	mM	





























































































Figure	3.7.	 Excitotoxic	 challenge	 to	 retinas	 as	 induced	by	 intravitreal	 injections	of	
10nmol	 NMDA	 led	 to	 significant	 losses	 of	 Brn3a-positive	 and	 γ-synuclein-positive	
cells.	 Prophylactic	 treatment	 with	 oral	 creatine	 did	 not	 result	 in	 any	 significant	
protection	from	this	cell	loss	(Student	T-test,	n	=	15-18).	Scale	bar	=	100	µM.	


















































mount	 preparations	 were	 labelled	 by	 the	 TUNEL	 reaction	 alongside	 anti-Brn3a	
antibodies,	 there	was	an	observed	 reduction	 in	Brn3a-positive	RGCs	as	well	 as	an	










Figure	 3.9.	 Immunofluorescence	 showing	 (A)	 Brn3a	 (red)	 and	 (B)	 TUNEL	 (green)	
labelling	of	retinal	whole-mounts	from	eyes	8-hours	post-NMDA	(10	nmol)	injection.	








































Figure	 3.11.	 Photomicrographs	 showing	 retinal	 histology	 in	 tissue	 cross-sections	
labelled	with	Brn3a	and	γ-synuclein	for	both	control/creatine-treated	eyes	(A-D)	and	
eyes	subjected	to	intravitreal	NMDA	(10	nmol)	injections,	7-days	post-treatment	(E-






	 Establishment	 of	 retinal	 ischaemia	 via	 acute	 elevation	 of	 IOP	 also	 caused	
significant	 reduction	 in	 numbers	 of	 RGCs	 after	 7	 days.	 Electroretinogram	 traces	
recorded	 from	 rats	 at	 7	 days	 after	 IOP	 elevation	 show	 significant	 loss	 of	 b-waves	


























Figure	 3.13.	 High	 intraocular	 pressure-induced	 retinal	 ischaemia	 (75	 min)	 led	 to	
































































Initial	 studies	 employed	 rat	 retinal	 cultures	 in	which	 a	metabolic	 dysfunction	was	
induced	 by	 using	 sodium	 azide	 to	 compromise	 mitochondrial	 oxidative	
phosphorylation.	We	previously	determined	in	rat	retinal	cultures	that	sodium	azide	
could	 reliably	 induce	 neuronal	 loss	 via	 oxidative	 stress,	mitochondrial	membrane	
disruption	and	energetic	dysfunction.151	In	the	present	study,	sodium	azide	caused	
significant	neuron	loss	in	both	acute	and	chronic	models	of	metabolic	dysfunction	in	
cultured	retinal	cells.	When	creatine	was	added	prophylactically	 to	see	 if	 it	would	
protect	 against	 sodium	 azide	 in	 the	 cultures,	 significant	 and	 concentration-




cells	 only.	 Observed	 neuronal	 protection	 is	 consistent	 with	 other	 in	 vitro	 studies	











study	 of	 neurodegenerative	 diseases	 since	 excitatory	 neurotoxicity	 has	 been	
proposed	 as	 one	 of	 the	 key	 mechanisms	 of	 injury	 in	 ocular	 neurodegenerative	
conditions,	 including	 glaucoma,	 retinal	 vessel	 occlusions	 and	 diabetic	
retinopathy.65,159,160	 It	 has	 been	 observed	 that	 within	 the	 CNS,	 accumulation	 of	
glutamate	in	the	extracellular	space	leads	to	neuronal	cell	death	via	various	pathways	
that	 may	 occur	 in	 parallel	 and	 result	 in	 both	 ongoing	 depolarization	 and	 self-
propagating	 injury.42,161,162	 Stimulation	 of	 depolarization	 via	 excitatory	
neurotransmitters	 (namely	 glutamate)	 results	 in	 voltage-dependent	 Na+	 influx	
followed	 by	 passive	 influx	 of	 Cl-.	 Water	 diffuses	 into	 neurons	 along	 the	 osmotic	
gradient	 and	 can	 cause	 osmotic	 shock	 and	 cell	 lysis	 –	 this	 type	 of	 cell	 death	 is	
categorised	as	necrosis.	At	the	same	time,	intracellular	Ca2+	levels	rise	due	to	multiple	
factors	 that	both	enhance	Ca2+	 influx	and	 reduce	Ca2+	 efflux.	 Such	 factors	 include	
activation	 of	 receptors	 or	 channels	 that	 allow	 direct	 entry	 of	 Ca2+	 into	 the	 cell,	
depletion	 of	 ATP	 due	 to	 the	 widespread	 over-action	 of	 receptors,	 mitochondrial	
dysfunction,	and	failure	of	Ca2+	extrusion	secondary	to	ATP	depletion.	 Increases	 in	
intracellular	 Ca2+	 levels	 in	 turn	 cause	 activation	 of	 destructive	 enzymes	 such	 as	




such	 as	 kainate.163,164	 These	 described	 processes	 are	 in	 line	 with	 a	 previously	
proposed	 hypothesis	 that	 considered	 excessive	 intracellular	 Ca2+	 as	 a	 trigger	 for	
neuronal	death,	namely	“calcium	loading”	hypothesis.65,165	NMDA	receptors	 in	the	
rat	retina	have	been	localized	on	RGCs	and	displaced	amacrine	cells	in	the	ganglion	









in	parallel	 as	 a	 result	 of	 ischaemia	as	mitochondrial	 function	 is	 compromised	and	



































induced	 excitotoxic	 neuronal	 death.94	 On	 the	 other	 hand,	 in	 a	 recent	 study,	
intracerebral	 β-amyloid	 injections	 were	 performed	 on	Wistar	 rats	 before	 feeding	
these	animals	on	a	diet	containing	2%	(w/w)	creatine	for	a	total	of	six	weeks.	At	the	
end	of	the	experiment,	several	tests	including	a	measure	for	learning	and	memory	
retrieval,	 as	 well	 as	 TUNEL	 staining	 on	 histological	 sections,	 did	 not	 show	 any	
significant	difference	between	the	creatine-treated	and	control	groups.168		
Mechanisms	of	Protection	
We	 showed	 in	 our	 in	 vitro	 studies	 that	 creatine	 was	 able	 to	 reduce	 both	
oxidative	 stress	 levels	 and	 incidences	 of	 apoptosis.	 The	 presented	 data	 were	 in	
agreement	with	previously	proposed	mechanisms	for	creatine	in	studies	related	to	
models	 of	 other	 neurodegenerative	 diseases.71,75-82,91,94,96,153,154,169-172	We	 did	 not,	
however,	detect	that	creatine	was	able	to	elevate	cellular	ATP	levels	 in	this	study.	
Previous	 studies	 have	 not	 clearly	 detected	 higher	 ATP	 levels	 in	 cultured	 neurons	
treated	with	 creatine,	but	did	 suggest	 a	 role	of	 creatine	 in	neuroprotection	as	 an	
energy	 buffer.	 In	 2007,	 Prass	 and	 colleagues,	 using	magnetic	 resonance	 imaging,	
found	an	augmented	cerebral	blood	flow	and	neuroprotection	in	creatine-fed	mice	
in	 a	 rodent	 model	 of	 cerebral	 ischaemia.171	 Wilken	 and	 colleagues	 treated	 rat	
mothers	with	anoxia	for	30	minutes	and	found	that	in	creatine-fed	animals	subjected	
to	the	same	insult,	histological	brain	slices	of	their	pups	showed	a	significantly	higher	
ATP	 levels.92	 On	 the	 other	 hand,	 Brewer	 and	 colleagues	 incubated	 hippocampal	
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neurons	 with	 creatine	 and	 showed	 protection	 against	 glutamate-induced	
excitotoxicity,	 but	 did	 not	 find	 a	 significantly	 higher	 ATP	 levels	 in	 the	 neuronal	
tissues.96	 However,	 their	 study	 did	 show	 that	 at	 the	 early	 stages	 of	 glutamate	
exposure,	 the	 phosphocreatine-to-ATP	 ratio	 was	 significantly	 higher	 in	 creatine-
treated	 neurons,	 although	 the	 creatine	 levels,	 themselves,	 were	 lower.	 They	
proposed	that	 this	change	 in	creatine	or	phosphocreatine	 levels	was	due	to	 initial	
conversion	of	new	intracellular	creatine	to	phosphocreatine	with	the	consumption	of	
ATP	(and	rise	in	phosphocreatine).	It	was	thought	that	these	early	changes	in	creatine	





It	 is	 well	 established	 that	 mitochondrial	 compromise	 via	 treatment	 with	









small	 amount	of	protection,	perhaps	 it	would	be	more	evident	 in	 a	model	where	
damage	is	less	pronounced	and	of	a	more	protracted	duration.		
Another	 explanation	 for	 the	 lack	 of	 effect	 seen	 by	 analysing	 RGC	
quantification	in	the	animal	models	is	that	the	prophylactic	treatment	of	creatine,	as	
applied	via	the	oral	route,	may	not	provide	a	sufficient	end-point	concentration	of	
this	 compound	 in	 the	 retina	 (i.e.	 insufficient	 dose).	 Compared	 to	 creatine	
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neuroprotection	 studies	 in	 other	 neurodegenerative	 disease	 models,	 however,	 it	
would	be	assumed	that	the	concentration	used	in	our	study	was	sufficient	(2%	w/w	
in	chow).	In	a	Parkinson	model,	for	example,	pretreatment	of	mice	with	1%	creatine	
(w/w	 in	 chow)	 for	 2	weeks	 prior	 to	MPTP	 injections	 almost	 completely	 abolished	
deleterious	effects	to	dopaminergic	neurons.77	Similarly,	in	studies	in	a	rodent	model	
of	 ALS,	 a	 dose-dependent	 increase	 in	 survival	 compared	 to	 placebo	 (reduction	 in	
neuronal	 cell	 death)	was	observed	with	1-2%	of	 creatine	 (in	 chow),	when	 started	
within	1-2	months	post-partum.79		
Future	Directions	
The	potential	use	of	 creatine	as	a	neuroprotective	 compound	 for	 the	 retina	





isolated	 RGC	 cultures	 are	 unable	 to	 consistently	 produce	 enough	 cells	 for	
quantification	purposes	in	neuroprotection	studies.	Further	mechanistic	studies	can	
be	performed	to	allow	greater	characterisation	of	the	effects	of	creatine	in	retinal	
cultures,	 such	 as	 tests	 for	 ATP	 levels	 and	mitochondrial	membrane	 potentials.	 In	







ganglion	 cells	 in	 animal	models	 of	 excitotoxicity.	 This	 discrepancy	 in	 its	 ability	 to	
provide	neuroprotection	needs	to	be	further	explored	and	validated.	Nonetheless,	
mechanistic	studies	have	shown	that	creatine	displays	antioxidant	and	anti-apoptotic	





Neurodegeneration	 of	 the	 retina	 accounts	 for	 a	 large	 group	 of	 retinal	
pathologies,	 including	 glaucoma,	 age-related	 macular	 degeneration	 and	 diabetic	
retinopathy.4,53,173,174	These	diseases	are	largely	managed	by	controlling	known	risk	
factors,	such	as	serum	glucose	levels	for	diabetic	patients	and	intraocular	pressure	
for	glaucoma	patients.	Despite	having	 in-depth	understanding	 (or	 theories)	of	 the	
process	of	neuronal	degeneration	at	the	molecular	level,	there	exist	little	means	to	
directly	 deal	 with	 these	 processes,	 such	 as	 oxidative	 stress	 and	 mitochondrial	
membrane	 potential	 instability.	 In	 the	 clinical	 setting,	 there	 are	 a	 significant	
proportion	 of	 cases	 where	 dealing	 with	 known	 risk	 factors	 still	 results	 in	
neurodegeneration,	 as	 is	 seen	 in	 the	 case	 of	 glaucoma.39,40	 There	 are	 several	
potential	 agents	 for	 potential	 application	 of	 neuroprotection	 that	 have	 been	
suggested	in	the	literature,	 including	the	guanidine	compound	creatine,	which	has	
recently	 been	 studied	 and	 shown	 to	 be	 neuroprotective	 in	 models	 of	 major	
neurodegenerative	diseases	of	the	central	nervous	system.42,73,91	This	study	explored	
the	 prospect	 of	 using	 creatine	 as	 a	 neuroprotective	 agent	 in	 the	 setting	 of	
neurodegeneration	 in	the	retina.	We	first	performed	a	study	to	compare	different	
markers	of	retinal	ganglion	cells	in	a	well-known	NMDA-induced	excitotoxicity	model.	









to	 be	 the	 case	 for	 creatine	 in	 our	 work.	 We	 therefore	 employed	
immunohistochemical	 labelling	 of	 retinal	 whole-mounts	 and	 tested	 a	 variety	 of	
antibody	 markers	 known	 to	 label	 RGCs	 for	 reproducibility,	 specificity,	 accurate	
dissemination	 of	 cell	 loss	 and	 good	 signal-to-noise	 ratio.	 Data	 showed	 that	
intravitreal	injection	of	NMDA	to	induce	retinal	toxicity	leads	death	of	at	least	90%	of	
the	RGC	population	within	the	first	24	hours	when	quantifying	cells	labelled	by	Brn3a,	















protection	 of	 up	 to	 50%	 of	 this	 loss.	 Assessment	 of	 the	 level	 of	 reactive	 oxygen	
species	in	this	model	e	showed	that	sodium	azide	produces	oxidative	stress	that	was	
significantly	reduced	by	prophylactic	treatment	with	creatine.	The	final	ATP	content	




























































the	 retina.94	 Fourthly,	 prophylactic	 creatine	 treatment	 in	 this	work	may	 not	 have	
been	applied	early	enough	before	induction	of	retinal	injury	to	reach	a	suitable	and	
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One	 limitation	 for	 our	 study	 was	 the	 lack	 of	 positive	 controls	 to	 compare	
creatine	to.	However,	it	is	difficult	to	search	for	a	neuroprotectant	that	has	the	same	
mechanism	of	action	as	 creatine	 in	protecting	 the	 retina	 from	various	 insults.	 For	
example,	MK801	has	been	shown	to	provide	neuroprotection	in	the	retina,	but	with	





We	used	 oral	 feeds	 for	 creatine	 to	 be	 administered	 because	 it	was	 proven	 to	 be	










energy	 buffering,	 mitochondrial	 stabilization	 and	 anti-apoptotic	 qualities	 can	 be	
more	extensively	investigated	in	the	context	of	retinal	neurodegeneration.	Models	of	
other	types	of	metabolic	dysfunction	can	be	implemented	to	fully	elucidate	creatine’s	
effects	 on	 retinal	 neurons.	 Certainly,	 cultures	 of	 specific,	 rather	 than	 mixed	
populations	of	cells,	such	as	RGCs,	could	be	employed	to	look	at	effects	of	creatine	
on	 specific	 cell	 types.	 However,	 single	 cell	 type	 cultures	 of	 the	 retina	 are	 often	
problematic	to	establish	and	cell	yield	is	often	not	enough	for	quantification	purposes.	
Aspects	of	fine-tuning	of	the	creatine	concentration	to	be	administered	as	well	as	the	
timing	 (prophylactic	duration)	can	also	be	 investigated	 in	both	culture	and	animal	
models.	For	in	vivo	work,	there	are	a	large	variety	of	types	of	injury	models	as	well	as	
types	 of	 retinal	 neurons	 to	 focus	 on,	 but	 perhaps	 a	 better	 step	 to	 take	 is	 to	 use	
reliable	models	of	oxidative	stress	and	energy	failure	at	a	much	lower	magnitude	of	
injury.	 Rats	 and	 mice	 remain	 useful	 animals	 for	 experimentation	 as	 they	 are	
inexpensive	 and	 easy	 to	 house.	 Although	 there	 is	 a	 high	 degree	 of	 conservation	
between	rodent	and	human	genomes,	the	anatomy	of	the	rodent	retina	is	not	similar	
to	humans	in	that	there	is	an	absence	of	lamina	cribrosa	in	the	optic	nerve	and	the	
very	 small	 globe	 size	 makes	 it	 hard	 to	 access	 clinically.177	 Monkeys	 have	 close	
phylogeny	and	high	homology	with	humans,	having	retinal	and	optic	nerve	anatomy	










may	 work	 in	 a	 separate	 pathway	 to	 reduce	 oxidative	 stress.	 Coenzyme	 Q10	 is	 a	










whether	 creatine	 is	 able	 to	 provide	 neuroprotection	 in	 retinal	 neurodegenerative	
diseases.	 Creatine	 is	 able	 to	 achieve	 partial	 neuroprotection	 in	 the	 retina	 from	
metabolic	dysfunction	–	likely	through	reduction	in	oxidative	stress	and	prevention	
of	cellular	apoptosis.	This	protection,	however,	is	yet	to	be	seen	in	animal	studies.	
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